The estimated Net Worth of James P Yee is at least 2.96 百万$ dollars as of 1 July 2019. James Yee owns over 20,000 units of Caredx Inc stock worth over 1,199,544$ and over the last 10 years James sold CDNA stock worth over 1,756,398$.
James has made over 5 trades of the Caredx Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently James sold 20,000 units of CDNA stock worth 713,000$ on 1 July 2019.
The largest trade James's ever made was selling 32,500 units of Caredx Inc stock on 12 February 2019 worth over 776,100$. On average, James trades about 4,968 units every 26 days since 2015. As of 1 July 2019 James still owns at least 42,045 units of Caredx Inc stock.
You can see the complete history of James Yee stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over 60,271,359$ worth of Caredx Inc stock and bought 1,726,634 units worth 9,072,700$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Neil Gagnon、Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of 615,506$. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth 1,432,820$.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: